Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic... (g molecules that killboth normal and tum...)

Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes

Date:8/29/2007

g molecules that kill both normal and tumor cells, the silenced genes are reactivated through targeted epigenetic therapy, re-establishing the cancer cell's natural mechanisms to control abnormal growth.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management, including statements related to the potential efficacy of oral Azacitidine and Vidaza. Such statements are based on current expectations and beliefs only and are subject to risks and uncertainties, many of which are beyond our control, which could cause the actual results to differ significantly from the results expressed or implied by such statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of product candidates, including oral Azacitidine, to demonstrate safety and efficacy in clinical and non-clinical testing; the possibility that topline results from the clinical trial discussed in this press release will not be confirmed upon full analysis of the results of the trial and that additional information relating to the safety, efficacy or tolerabili
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Mirus granted European patent for gene therapy
2. Platypus granted new liquid crystal patent
3. WARF Granted New Antibiotics Patent
4. Identity theft start up has fast-track growth plans
5. In pursuit of capital, be sure to track your private offering
6. Jellyfish partners for sales tracking technology
7. Medical College team creates website for tracking flu
8. Johnson Controls deals for asset-tracking software
9. RFID system aids hospital in tracking assets
10. State tracks more angel investment, at least $19M last year
11. On track with the FDA -- But what about your coverage and reimbursement strategy?

Post Your Comments:

Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic...(g molecules that killboth normal and tum...)